Drug intelligence / Profile preview

CHO-H03

Development stage: Preclinical
Lead developer: Cho Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Parenteral (likely Intravenous Or Subcutaneous)

Overview

CHO-H03 is a glycoengineered monoclonal antibody developed using the proprietary CHOptimax technology by CHO Pharma, originally from Academia Sinica. It is designed to alleviate inflammatory conditions in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease. The drug displays increased FcγR binding and induces regulatory macrophages with anti-inflammatory properties that are important for mucosal healing. Its specific glycoform is expected to reduce the generation of anti-agalactosyl IgG, potentially enhancing half-life and therapeutic benefit. As an immunomodulator antibody, it aims to modulate immune responses rather than directly targeting a single antigen[1][2][3].

Other names: CHO H03

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on CHO-H03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHO-H03.

Explore the full profile